Chromium (VI) promotes EMT by regulating FLNA in BLCA

Area of Science:

• Environmental toxicology
• Cancer biology
• Molecular oncology

Background:

• Hexavalent chromium (Cr (VI)) is a known human carcinogen prevalent in industrial settings.
• Environmental contaminants, including Cr (VI) in urine, are linked to urinary bladder tract malignant transformation.
• The precise molecular mechanisms by which Cr (VI) drives bladder cancer (BLCA) remain incompletely understood.

Purpose of the Study:

• To investigate the molecular mechanisms underlying Cr (VI)-induced bladder cancer (BLCA) progression.
• To identify key molecular targets involved in Cr (VI) carcinogenicity in BLCA.
• To explore the role of Filamin A (FLNA) in Cr (VI)-mediated BLCA development.

Main Methods:

• Analysis of FLNA expression in BLCA tissues.
• In vitro studies assessing the effects of Cr (VI) on BLCA cell proliferation, migration, and apoptosis.
• Investigation of Cr (VI)'s impact on epithelial-to-mesenchymal transition (EMT) and FLNA regulation in BLCA cells.

Main Results:

• Filamin A (FLNA) is significantly overexpressed in bladder cancer (BLCA) tissues.
• Cr (VI) exposure was found to promote BLCA cell proliferation and migration while inhibiting apoptosis.
• Cr (VI) induces epithelial-to-mesenchymal transition (EMT) in BLCA cells, a process mediated by the regulation of FLNA.

Conclusions:

• Filamin A (FLNA) is overexpressed in bladder cancer (BLCA) and plays a crucial role in Cr (VI)-induced tumor progression.
• Cr (VI) promotes BLCA cell proliferation, migration, and epithelial-to-mesenchymal transition (EMT) by regulating FLNA.
• Inhibiting FLNA expression presents a potential therapeutic strategy to counteract Cr (VI)-induced bladder cancer (BLCA) progression.